REPLOID Group Aktie 146541228 / AT0000A3HRX5
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
|
03.10.2025 12:00:08
|
EQS-Adhoc: REPLOID Group AG: REPLOID Group AG acquires stake in HEROSAN Healthcare GmbH – strategic focus on sustainable animal feed products and production.
|
EQS-Ad-hoc: REPLOID Group AG / Key word(s): Mergers & Acquisitions/Alliance Wels, 3 October 2025
REPLOID Group AG announces that it is acquiring a stake in HEROSAN Healthcare GmbH, thereby expanding its involvement in the fast-growing markets for sustainable animal feed products and production. The acquisition of the company will take place in two phases. In 2025, REPLOID Group AG will acquire more than 30% of the company's shares, with a view to increasing its stake to 100% in 2026 via a notarised ‘step-up option’. HEROSAN pursues a clear, Europe-wide growth strategy focused on sustainability, responsibility and healthy animal nutrition. With a wide range of products from feed mixes with hemp and insect protein to functional mushroom components and selected meat products, HEROSAN positions itself as a supplier of a high-quality premium product range for pets in specialist shops, food retailers and e-commerce. With its entry into HEROSAN, REPLOID Group AG is strategically expanding its investment portfolio to include a company with very strong growth potential in a promising market segment. The aim of this investment and cooperation is to position HEROSAN as one of Europe's leading feed producers in the coming years. End of Inside Information Information and Explanation of the Issuer to this announcement: Important note This announcement is a mandatory disclosure of inside information pursuant to Article 17 of the Market Abuse Regulation (EU) No 596/2014. It does not constitute financial analysis or advice or a recommendation relating to financial instruments, nor does it constitute an offer, solicitation or invitation to buy or sell securities of REPLOID Group AG.
03-Oct-2025 CET/CEST News transmitted by EQS Group. www.eqs.com |
| Language: | English |
| Company: | REPLOID Group AG |
| Maria-Theresia-Strasse 53 | |
| 4600 Wels | |
| Austria | |
| Phone: | +43 660 / 776 50 40 |
| E-mail: | office@reploid.eu |
| Internet: | reploid.eu |
| ISIN: | AT0000A3HRX5 |
| Listed: | Vienna Stock Exchange (Vienna MTF) |
| EQS News ID: | 2207210 |
| IPO geplant, IPO planned; |
| End of Announcement | EQS News Service |
|
|
2207210 03-Oct-2025 CET/CEST
Nachrichten zu REPLOID Group AG Inhaber-Akt
Analysen zu REPLOID Group AG Inhaber-Akt
Im BX Morningcall werden folgende Aktien analysiert und erklärt – heute mit dem monatlichen Rebalancing:
NEU✅ KLA-Tencor
NEU✅ Applied Materials
NEU✅ Banco Bilbao Vizcaya Argentaria SA
inklusive Rebalancing:
❌ Manhattan Associates Inc
❌ Euronext N.V.
❌ Intercontinental Exchange
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| REPLOID Group AG Inhaber-Akt | 1’780.00 | 0.00% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Nach Arbeitsmarktdaten: US-Börsen schliessen mit Gewinnen -- SMI beendet Handel fester -- DAX dreht letztlich ins Plus -- Asiens Börsen schlussendlich uneinsAm heimischen Aktienmarkt ging es am Mittwoch freundlich zu. Der deutsche Aktienmarkt konnte seine Verluste abschütteln. An der Wall Street wurden Gewinne verzeichnet. An den asiatischen Aktienmärkten geht es zur Wochemitte in unterschiedliche Richtungen.